Your Health, We Care
Release date: 2026-04-30 16:37:50 Recommended: 3
The starting dose of finerenone depends on the patient's indication, baseline eGFR, and serum potassium level. For patients with heart failure and LVEF ≥40%, if eGFR is ≥60 mL/min/1.73m², the recommended starting dose is 20 mg once daily; if eGFR is between 25-59 mL/min/1.73m², the starting dose is 10 mg once daily. For patients with chronic kidney disease and type 2 diabetes mellitus, the starting dose is similarly stratified by eGFR: 20 mg for eGFR ≥60, and 10 mg for eGFR 25-59. Serum potassium and eGFR must be rechecked 4 weeks after treatment initiation or dose adjustment. If serum potassium >5.5 mEq/L, temporary interruption or dose reduction is required; if eGFR decreases by more than 30% from baseline, the current dose should be maintained. For patients unable to swallow whole tablets, the tablet can be crushed and immediately mixed with water or soft food (e.g., jam). Patients should be advised to avoid concomitant intake of grapefruit or grapefruit juice. If a dose is missed, it should be taken on the same day, otherwise skip the missed dose.
Excessive mineralocorticoid receptor activation is one of the key drivers of the progression of heart failure and chronic kidney disease, leading to sodium and fluid retention, inflammation, fibrosis, and cardiac hypertrophy. Finerenone, as the only nonsteroidal MRA, selectively and potently blocks excessive mineralocorticoid receptor activation, thereby simultaneously protecting the heart and kidneys. Compared with traditional steroidal MRAs (e.g., spironolactone, eplerenone), finerenone has distinct pharmacokinetic and pharmacodynamic properties. The half-lives of active metabolites of steroidal MRAs vary considerably; for example, canrenone, the active metabolite of spironolactone, has a half-life of 16.5 hours. In contrast, due to its nonsteroidal structure, finerenone demonstrates more balanced receptor selectivity and tissue distribution. Preclinical animal models have shown that finerenone effectively inhibits mineralocorticoid receptor-mediated injury signaling pathways in both cardiomyocytes and glomerular podocytes. While the clinical consequences require further validation, observed outcomes such as reduction in the urine albumin-to-creatinine ratio and reduction in hospitalizations for heart failure support its target-mediated benefit. Importantly, finerenone has no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors, which explains the clinical finding that the incidence of sex hormone-related adverse reactions (e.g., gynecomastia, sexual dysfunction, abnormal bleeding) is similar to that of placebo.
Multiple authoritative guidelines have positioned finerenone as a foundational treatment pillar for patients with chronic kidney disease and type 2 diabetes mellitus. The American Association of Clinical Endocrinologists (AACE) guideline gives a Grade 1A recommendation, the European Society of Cardiology (ESC) guideline also gives a Class I Level A recommendation, the American Diabetes Association (ADA) guideline gives an A-level recommendation, and the Kidney Disease: Improving Global Outcomes (KDIGO) guideline gives a Grade 2A recommendation. These A-level or Class I Level A recommendations are all based on large, well-designed randomized controlled trials, indicating high-quality evidence for finerenone in improving patient outcomes. For patients with heart failure and LVEF ≥40%, finerenone is the only nonsteroidal MRA approved by the FDA and is also recommended as a core component of a comprehensive treatment strategy, which can be used in combination with background therapies such as angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, and SGLT2i.
